Indoco Remedies Ltd vs Shukra Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Indoco Remedies Ltd is ₹ 213.9 as of 04 May 11:13 . The P/E Ratio of Indoco Remedies Ltd changed from 28.6 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Shukra Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Indoco Remedies Ltd changed from ₹ 2658 crore on March 2021 to ₹ 2152 crore on March 2025 . This represents a CAGR of -4.14% over 5 yearsThe Market Cap of Shukra Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Indoco Remedies Ltd for the Dec '25 is ₹ 446.34 crore as compare to the Sep '25 revenue of ₹ 485.43 crore. This represent the decline of -8.05% The revenue of Shukra Pharmaceuticals Ltd for the Dec '25 is ₹ 39.95 crore as compare to the Sep '25 revenue of ₹ 7.59 crore. This represent the growth of 426.35% The ebitda of Indoco Remedies Ltd for the Dec '25 is ₹ 26.34 crore as compare to the Sep '25 ebitda of ₹ 43.28 crore. This represent the decline of -39.14% The ebitda of Shukra Pharmaceuticals Ltd for the Dec '25 is ₹ 27.95 crore as compare to the Sep '25 ebitda of ₹ 1.29 crore. This represent the growth of 2066% The net profit of Indoco Remedies Ltd changed from ₹ -28.4 crore to ₹ -29.45 crore over 7 quarters. This represents a CAGR of 2.10% The net profit of Shukra Pharmaceuticals Ltd changed from ₹ 3.16 crore to ₹ 20.36 crore over 7 quarters. This represents a CAGR of 189.96% The Dividend Payout of Indoco Remedies Ltd changed from 14.96 % on March 2021 to -21.11 % on March 2025 . This represents a CAGR of NaN% over 5 yearsThe Dividend Payout of Shukra Pharmaceuticals Ltd changed from 10.47 % on March 2022 to 4.57 % on March 2025 . This represents a CAGR of -18.72% over 4 years .

About Indoco Remedies Ltd

Indoco Remedies Limited, incorporated on August 23, 1947 is a Mumbai-based pharmaceutical company focused on formulations, with some presence in contract manufacturing and research.
The Company headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries.
The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). Indoco, a USD 212 million company has 11 manufacturing facilities, 7 of which are for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. Currently, Indoco has a presence in therapeutic segments including anti-infective, anti-cold preparation, opthalmic, antispasmodic, stomatology, anti-inflammatory and anti-fungal.

About Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Limited, formerly known Relish Pharmaceuticals Limited was established in March, 1993 and later on the Company name was changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on September 22, 2016.
The Company is presently engaged in the business of manufacturing and trading of pharmaceuticals formulations and laboratory testing. The company provides varieties of products to the clientele.
Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others.

FAQs for the comparison of Indoco Remedies Ltd and Shukra Pharmaceuticals Ltd

Which company has a larger market capitalization, Indoco Remedies Ltd or Shukra Pharmaceuticals Ltd?

Market cap of Indoco Remedies Ltd is 1,937 Cr while Market cap of Shukra Pharmaceuticals Ltd is 1,272 Cr

What are the key factors driving the stock performance of Indoco Remedies Ltd and Shukra Pharmaceuticals Ltd?

The stock performance of Indoco Remedies Ltd and Shukra Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Indoco Remedies Ltd and Shukra Pharmaceuticals Ltd?

As of May 4, 2026, the Indoco Remedies Ltd stock price is INR ₹209.9. On the other hand, Shukra Pharmaceuticals Ltd stock price is INR ₹29.07.

How do dividend payouts of Indoco Remedies Ltd and Shukra Pharmaceuticals Ltd compare?

To compare the dividend payouts of Indoco Remedies Ltd and Shukra Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.